Hemostemix's Social Media for Investors and Florida's No-Option Patients
Hemostemix (OTCQB: HMTXF) has announced an enhanced investor awareness and social media strategy for its autologous stem cell therapy platform VesCell™. The company has reported $1,143,983 in Therapy Convertible Debenture sales year-to-date and is expanding its presence in Florida.
The company's treatment platform has demonstrated significant clinical results, including up to 47.1% increase in ejection fraction in cardiomyopathy patients and a 99% reduction in ulcerating wounds in Phase II CLTI trials. With 498 treatments completed and 11 peer-reviewed publications, Hemostemix is leveraging multiple social media platforms to reach both investors and potential patients suffering from various cardiovascular conditions.
Hemostemix (OTCQB: HMTXF) ha annunciato una strategia rafforzata di awareness per gli investitori e di presenza sui social media per la sua piattaforma di terapia con cellule staminali autologhe VesCell™. La società segnala $1.143.983 in vendite di Debentures Convertibili Therapy da inizio anno e sta ampliando la propria attività in Florida.
La piattaforma terapeutica ha mostrato risultati clinici rilevanti, tra cui fino al 47,1% di incremento della frazione di eiezione nei pazienti con cardiomiopatia e una riduzione del 99% delle lesioni ulcerative nei trial di Fase II per CLTI. Con 498 trattamenti completati e 11 pubblicazioni su riviste peer-reviewed, Hemostemix sfrutta più canali social per raggiungere sia gli investitori sia i pazienti potenziali affetti da diverse patologie cardiovascolari.
Hemostemix (OTCQB: HMTXF) ha anunciado una estrategia ampliada de concienciación para inversores y de redes sociales para su plataforma de terapia con células madre autólogas VesCell™. La compañía informa de $1,143,983 en ventas de Obligaciones Convertibles Therapy en lo que va de año y está ampliando su presencia en Florida.
La plataforma de tratamiento ha mostrado resultados clínicos destacados, incluyendo hasta un 47,1% de aumento en la fracción de eyección en pacientes con cardiomiopatía y una reducción del 99% de heridas ulceradas en ensayos de Fase II para CLTI. Con 498 tratamientos completados y 11 publicaciones revisadas por pares, Hemostemix está utilizando múltiples redes sociales para llegar tanto a inversores como a pacientes potenciales con diversas afecciones cardiovasculares.
Hemostemix (OTCQB: HMTXF)는 자가 줄기세포 치료 플랫폼 VesCell™에 대한 투자자 인지도 및 소셜 미디어 전략을 강화했다고 발표했습니다. 회사는 연초 대비 Therapy 전환사채 판매액 $1,143,983을 보고했으며 플로리다에서의 활동을 확장하고 있습니다.
치료 플랫폼은 임상적으로 의미 있는 결과를 보였습니다. 심근병증 환자에서 최대 좌심실 박출률 47.1% 증가와 CLTI 2상 시험에서 궤양성 상처 99% 감소를 기록했습니다. 498회 치료 완료와 11건의 동료 심사 논문을 바탕으로 Hemostemix는 여러 소셜 미디어 채널을 활용해 투자자와 다양한 심혈관 질환을 앓는 잠재 환자들에게 다가가고 있습니다.
Hemostemix (OTCQB: HMTXF) a annoncé une stratégie renforcée de sensibilisation des investisseurs et de présence sur les réseaux sociaux pour sa plateforme de thérapie par cellules souches autologues VesCell™. La société fait état de 1 143 983 $ de ventes de Therapy Convertible Debentures depuis le début de l'année et étend sa présence en Floride.
La plateforme thérapeutique a démontré des résultats cliniques significatifs, incluant jusqu'à 47,1 % d'augmentation de la fraction d'éjection chez des patients atteints de cardiomyopathie et une réduction de 99 % des plaies ulcérées lors des essais de phase II pour la CLTI. Avec 498 traitements réalisés et 11 publications évaluées par des pairs, Hemostemix exploite plusieurs plateformes sociales pour atteindre à la fois les investisseurs et les patients potentiels souffrant de diverses affections cardiovasculaires.
Hemostemix (OTCQB: HMTXF) hat eine verstärkte Investor-Awareness- und Social-Media-Strategie für seine autologe Stammzelltherapie-Plattform VesCell™ angekündigt. Das Unternehmen meldet $1.143.983 an Verkäufen von Therapy Convertible Debentures bisher in diesem Jahr und baut seine Präsenz in Florida aus.
Die Behandlungsplattform zeigte signifikante klinische Ergebnisse, darunter bis zu 47,1% Steigerung der Ejektionsfraktion bei Kardiomyopathie-Patienten und eine 99%ige Reduktion ulcerierender Wunden in Phase-II-CLTI-Studien. Mit 498 abgeschlossenen Behandlungen und 11 peer-reviewed Publikationen nutzt Hemostemix mehrere Social-Media-Kanäle, um sowohl Investoren als auch potenzielle Patienten mit verschiedenen kardiovaskulären Erkrankungen zu erreichen.
- None.
- None.
Calgary, Alberta--(Newsfile Corp. - August 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering treatments for no-option patients in Florida suffering from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease, Angina, Ischemic Cardiomyopathy, non Ischemic Dilated Cardiomyopathy, and Congestive Heart Failure, is pleased to announce additions to its investor awareness and social media strategies and programs.
The investor outreach campaign includes:
- Opt-in SMS alerts to keep existing and prospective investors updated on corporate milestones - text 905-580-4170 to opt-in.
- Targeted opt-in email provides company news, clinical developments, and financing updates: email: sfarooquoi@hemostemix.com,
- Investor platforms and exchanges (https://www.otcmarkets.com/stock/HMTXF/overview) are designed to increase Hemostemix's visibility, providing due diligence level information that retail and institutional audiences seek about our Company's investment opportunities.
"Hemostemix has sold forward
Campaign Strategy & Key Highlights - Testimonials and Publications
- Storytelling: Real patient testimonials about improved cardiac function, reduction of pain and ulcer healing make the science and treatment relatable and compelling.
- TIME Magazine highlighted VesCell™ recipient, Bob Grinstead, in Take Heart.
- Watch six time Grammy award winner and VesCell™ recipient Howie Lindeman.
- Watch Beefsto's Founder, VesCell™ patient #57, Neim Malo.
- Platform Utilization:
- Instagram & Facebook: Hemostemix has shared emotionally driven visuals and success narratives to connect directly with patients, caregivers, and broader communities.
- LinkedIn: Tailored for professionals and investors—Hemostemix is highlighting our clinical milestones, innovations, and corporate positioning.
- X: Thomas Smeenk, CEO, @HeartRepairGuy, is providing quick, timely updates, and engagement with practitioners and investor audiences.
- YouTube: Hemostemix posts its longer-form video content including its weekly webinars and VesCell™ patient testimonials:
- Results Emphasized in Posts:
- Cardiac Improvements of up to a
47.1% increase in ejection fraction (LVEF%) in dilated cardiomyopathy patients after one treatment, Schubart et al, Stem Cell Research and Therapy. - Phase II CLTI: a
99% reduction in ulcerating wounds size, reduced from a mean of 146 mm² to 0.48 mm² by the end of month three (p=0.01), Henderson et al, JBRES1876.
- Cardiac Improvements of up to a
- Dual Audience Targeting: The campaign bridges two primary goals:
- Patient Recruitment: Demonstrating hope, safety, and effectiveness of VesCell™ for no-option CLTI, PAD, and heart patients.
- Liquidity for Investors: Educating investors and shareholders about the HEM's asymmetrical investment upside, using scientifically validated results and milestones achieved.
Summary Table
| Platform | Primary Focus |
| Visual stories of healing and clinical transformation | |
| Patient-centric storytelling and community engagement | |
| Corporate, investor, and scientific communications | |
| YouTube | In-depth video testimonials and informational content |
| X | Brief updates, engagement with the medical & investor audience |
ABOUT HEMOSTEMIX
Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell™ (ACP-01). A recent peer-reviewed article in Cells (June 29, 2025) provides the scientific foundation for how ACP-01 and NCP-01 may enhance brain-computer interface performance by reducing inflammation, fostering angiogenesis and synaptic plasticity, and potentially extending implant longevity. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of
For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder: EM: tsmeenk@hemostemix.com / PH: 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the Company's social media campaign strategy in furtherance of sales of VesCell™ (ACP-01), and the commercialization of ACP-01 via the sale of compassionate treatments under Florida SB 1768. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/263206
FAQ
What clinical results has Hemostemix (HMTXF) reported for its VesCell therapy?
How many treatments has Hemostemix (HMTXF) completed with VesCell?
What conditions does Hemostemix's (HMTXF) VesCell therapy treat?
How much has Hemostemix (HMTXF) raised in convertible debentures in 2025?
What social media platforms is Hemostemix (HMTXF) using for investor outreach?
